Live Events

QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™

Japan: February 26, 2026 - 1:00 - 5:00 pm | Korea: Wednesday, March 4, 2026…

CertaraDecember 9, 2025

Blog

Virtual triplets: The next step in personalized and ethical drug development

Learn how virtual triplets, linking PBPK, QSP, and organ-on-a-chip technologies, are transforming model-informed drug development,…

CertaraDecember 9, 2025

Fact Sheet

Expedited Pharmacometrics Regulatory Submissions

Certara delivers complete, compliant pharmacometric regulatory submission packages in just 4–6 weeks, eliminating the PMx…

CertaraDecember 8, 2025

Publication

Therapeutic drug monitoring of amikacin in Chinese premature infant: a population pharmacokinetic analysis and dosage optimization.

See how PopPK modelling in Chinese premature infants identifies key covariates and supports model‑based amikacin…

CertaraDecember 6, 2025

Announcement

Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings

Certara launches an expedited Pharmacometrics (PMx) Regulatory Submission service that cuts submission timelines in half.

CertaraDecember 3, 2025

Publication

Comparative Pharmacokinetics of Lutein and Zeaxanthin from Phospholipid, Liposomal, and MCT Formulations in SD Rats

Learn how phospholipid‑based formulations significantly increased lutein and zeaxanthin exposure versus MCT oil, analysed using…

CertaraDecember 2, 2025

Publication

History and Evolution of Innovations in Clinical Pharmacology

This paper reviews how decades of scientific and technological advances have transformed clinical pharmacology and…

Danielle PillsburyNovember 26, 2025

Publication

Modeling amyloid plaque turnover dynamics improves characterization of drug effects

Researchers modeled how amyloid plaques form and clear in Alzheimer’s disease, helping explain how treatments…

CertaraNovember 26, 2025

Blog

The stepwise PIP is here to stay: From pilot flexibility to permanent EU regulation

The stepwise Paediatric Investigation Plan (PIP) is a strategic, flexible route for drug developers navigating…

CertaraNovember 26, 2025

Publication

Dosing Optimization of Lamotrigine in Peripregnancy Epilepsy Through PopPK Modelling and Simulation

Find out how PopPK modelling shows major gestational changes in lamotrigine clearance and supports precise…

CertaraNovember 20, 2025

Modeling and Simulation

QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™

Virtual triplets: The next step in personalized and ethical drug development

Expedited Pharmacometrics Regulatory Submissions

Therapeutic drug monitoring of amikacin in Chinese premature infant: a population pharmacokinetic analysis and dosage optimization.

Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings

Comparative Pharmacokinetics of Lutein and Zeaxanthin from Phospholipid, Liposomal, and MCT Formulations in SD Rats

History and Evolution of Innovations in Clinical Pharmacology

Modeling amyloid plaque turnover dynamics improves characterization of drug effects

The stepwise PIP is here to stay: From pilot flexibility to permanent EU regulation

Dosing Optimization of Lamotrigine in Peripregnancy Epilepsy Through PopPK Modelling and Simulation

Newsletter sign up

Quick links

Solutions

Contact